Literature DB >> 26630458

Running for your life: A review of physical activity and cardiovascular disease risk reduction in individuals with schizophrenia.

Claire Chalfoun1, Antony D Karelis2, Emmanuel Stip1,3, Amal Abdel-Baki1,3,4.   

Abstract

Individuals with schizophrenia have a greater risk for cardiometabolic risk factors (e.g. central obesity, insulin resistance, hypertension and dyslipidaemia), cardiovascular diseases and mortality. This risky profile may be explained by the adverse effects of antipsychotic medications and an unhealthy lifestyle (e.g. smoking, poor nutrition and low physical activity). In the general population, physical activity has been shown to be the optimal strategy to improve both cardiometabolic parameters and cardiorespiratory fitness levels. Accordingly, an emerging literature of non-pharmacological interventions (e.g. cognitive behavioural therapy, diet and physical activity) has been studied in individuals with schizophrenia. Therefore, the purpose of this review was 1) to conduct a critical literature review of non-pharmacological interventions that included some kind of physical activity (including supervised and unsupervised exercise training) and target cardiometabolic risk factors in individuals with schizophrenia. 2) To describe the contribution of physical activity alone by reviewing trials of supervised exercise training programmes only. A literature review via systematic keyword search for publications in Medline, PubMed, Embase and PsycINFO was performed. Many non-pharmacological interventions are efficient in reducing cardiovascular disease risk factors when combined with physical activity. Supervised physical activity has been successful in decreasing cardiovascular disease risk, and aerobic interval training appears to provide more benefits by specifically targeting cardiorespiratory fitness levels. In conclusion, physical activity is an effective strategy for addressing cardiovascular disease risk in individuals with schizophrenia. Long-term studies are needed to evaluate the feasibility and impact of exercise training programmes in individuals with schizophrenia.

Entities:  

Keywords:  Aerobic interval training; cardiorespiratory fitness; metabolic complications; non-pharmacological interventions; psychosis

Mesh:

Substances:

Year:  2015        PMID: 26630458     DOI: 10.1080/02640414.2015.1119875

Source DB:  PubMed          Journal:  J Sports Sci        ISSN: 0264-0414            Impact factor:   3.337


  5 in total

1.  A web-based adapted physical activity program (e-APA) versus health education program (e-HE) in patients with schizophrenia and healthy volunteers: study protocol for a randomized controlled trial (PEPSY V@Si).

Authors:  Maxime Tréhout; Elise Leroux; Lucile Bigot; Solenne Jego; Pascal Leconte; Emmanuel Reboursière; Rémy Morello; Pierre-Alexandre Chapon; Aline Herbinet; Gaëlle Quarck; Sonia Dollfus
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-05-26       Impact factor: 5.270

2.  Physical Activity, Exercise and Sport Programs as Effective Therapeutic Tools in Psychosocial Rehabilitation.

Authors:  Federica Sancassiani; Sergio Machado; Antonio Preti
Journal:  Clin Pract Epidemiol Ment Health       Date:  2018-02-21

3.  Nonpharmacological Interventions for the Treatment of Cardiometabolic Risk Factors in People With Schizophrenia-A Systematic Review.

Authors:  Ewa Tumiel; Adam Wichniak; Marek Jarema; Michał Lew-Starowicz
Journal:  Front Psychiatry       Date:  2019-08-16       Impact factor: 4.157

4.  Effects of six weeks outdoor versus treadmill running on physical fitness and body composition in recreationally active young males: a pilot study.

Authors:  Gaurav Singh; Gaurav Kushwah; Tanvi Singh; Rodrigo Ramírez-Campillo; Rohit K Thapa
Journal:  PeerJ       Date:  2022-07-27       Impact factor: 3.061

5.  The Impact of General Medical Conditions in Obsessive-Compulsive Disorder.

Authors:  Andrea Aguglia; Maria Salvina Signorelli; Umberto Albert; Giuseppe Maina
Journal:  Psychiatry Investig       Date:  2018-02-22       Impact factor: 2.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.